Arvinas, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Randy Teel
- Full Time Employees
- 246
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 5 Science Park New Haven CT United States of America 06511
- IPO Date
- Sep 27, 2018
- CIK
- 0001655759
- Website
- arvinas.com
- Similar Companies
- Business
- Arvinas, Inc. (ARVN) is a clinical-stage biopharmaceutical company that develops protein degradation therapies using its proprietary PROTAC (PROteolysis TArgeting Chimera) platform to create small molecule drugs targeting disease-causing proteins for degradation. The company focuses on oncology and neuroscience indications, with lead product candidates including vepdegestrant (ARV-471), an oral PROTAC estrogen receptor degrader in Phase 3 clinical trials for ER+/HER2- advanced breast cancer; ARV-766, an oral PROTAC androgen receptor degrader in Phase 2 trials for prostate cancer; and ARV-102, a PROTAC targeting BCL6 for diffuse large B-cell lymphoma. Its PROTAC platform enables the design of molecules that hijack the body's ubiquitin-proteasome system to selectively degrade proteins previously considered "undruggable"; services include discovery research collaborations leveraging this technology for undisclosed targets. Arvinas operates primarily in the United States, with global clinical trial sites across North America, Europe, and Asia-Pacific; the company was founded in 2015 and maintains headquarters in New Haven, Connecticut. Recent developments include a strategic collaboration expansion with Pfizer Inc. in 2024 to advance PROTAC development for additional targets, positive Phase 3 interim data for vepdegestrant reported in mid-2025 supporting accelerated regulatory approval pathways, and a $1 billion financing round closed in early 2025 to fund late-stage trials and platform expansion into autoimmune diseases.
Company News
Arvinas to Present Novel Biomarker Data from the Phase 1 Clinical Trial for ARV-102, a PROTAC LRRK2 Degrader, at the 2026 International Congress of Parkinson's Disease and Movement Disorders®
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company's First Immuno-Oncology Candidate
Arvinas, Inc. (ARVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Arvinas to Participate in Upcoming Investor Conferences
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Connor Clark & Lunn Investment Management Ltd. Invests $1.39 Million in Arvinas, Inc. $ARVN
Arvinas: Veppanu Approval Underlines Degrader Platform Promise - I'm Bullish
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Arvinas Q2 Earnings Call Highlights
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call Transcript
Arvinas Q2 Earnings Call Highlights
Arvinas, Inc. (ARVN) Beats Q2 Earnings and Revenue Estimates
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
Arvinas Sharpens Pipeline Focus After First PROTAC Approval, Eyes Key Trial Data
Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas to Present at Jefferies Global Healthcare Conference
Arvinas Employees Give Back During Company-wide Impact Day
These Analysts Increase Their Forecasts On Arvinas After Q1 Results